Risk of cancer of the prostate and of the kidney parenchyma following bladder cancer

被引:0
|
作者
Fabbri, Carla
Ravaioli, Alberto
Ravaioli, Alessandra
Bucchi, Lauro
Balducci, Chiara
Canuti, Debora
Desiderio, Franco
Foca, Flavia
Panzini, Ilaria
Falcini, Fabio
机构
[1] Infermi Hosp, Dept Oncol, I-47900 Rimini, Italy
[2] Romagna Canc Registry, Ist Oncol Romagnolo, Forli, Italy
[3] Pierantoni Hosp, Dept Oncol, Forli, Italy
关键词
bladder cancer; incidence; second primary cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims and background: A registry-based cohort study of male patients with bladder cancer was conducted to determine the relative risk of second primary cancer of the prostate and kidney, the uni-/multivariate differences in relative risk according to patient characteristics, the cumulative risk by duration of the follow-up, and the prevalence: incidence ratio of prostate and kidney cancer cases detected in the first 6 months after the diagnosis of bladder cancer. Methods: The complete case records of all male patients (n = 2025) diagnosed with bladder cancer between 1986 and 2002 were extracted from the database of the Romagna Cancer Registry: 1539 patients were eligible for analysis of the incidence of following prostate and kidney cancers, of the relative risk and the standardized incidence ratio specific for the time interval of follow-up. Results: A total of 108 prostate cancer cases and 23 kidney cancer cases were observed during the follow-up. The relative risk of second primary cancer of the prostate and kidney was respectively 3.52 (95% Cl, 2.89-4.25) and 3.90 (95% Cl, 2.47-5.85). The absolute excess risk was 11.8 x 1000 for prostate cancer and 2.5 x 1000 for kidney cancer. The number of prevalent cases of prostate and kidney cancer detected was approximately 10 times greater than the expected number based on incidence rates from the general population. During the follow-up, incidence of prostate cancer stabilized at a level that was 3- to 4-fold greater than that expected. Despite fluctuations, a decrease was also observed for incidence of kidney cancer. Conclusions: In summary, our study showed the relatively constant high incidence of prostate and kidney cancers in bladder cancer patients over time. The possibility of subsequent cancer implies that an appropriate long surveillance is required. The pertinence depends on the duration of the follow-up as well as the degree of surveillance.
引用
收藏
页码:124 / 128
页数:5
相关论文
共 50 条
  • [31] Clinical and histopathological features of bladder cancer following radiotherapy for prostate cancer: A comparative study
    Schernuk, Jordan
    Gonzalez, Matias I.
    Vecchio, Florencia
    Alfieri, Andres G.
    Tobia, Ignacio P.
    Tejerizo, Juan C.
    Favre, Gabriel A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (11) : 492.e1 - 492.e6
  • [32] Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer
    Stabile, Armando
    Muttin, Fabio
    Zamboni, Stefania
    Moschini, Marco
    Gandaglia, Giorgio
    Fossati, Nicola
    Dell'Oglio, Paolo
    Capitanio, Umberto
    Cucchiara, Vito
    Mazzone, Elio
    Bravi, Carlo A.
    Mirone, Vincenzo
    Montorsi, Francesco
    Briganti, Alberto
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (09) : 739 - 755
  • [33] SYNCHRONOUS PRIMARY MULTIPLE CANCER OF THE KIDNEY, URINARY-BLADDER AND PROSTATE
    VOROBYEV, A
    BYSTROVA, VV
    KOLOMOITSEV, SV
    ROZOVA, SL
    VOPROSY ONKOLOGII, 1989, 35 (10) : 1256 - 1257
  • [34] Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer
    Cimadamore, Alessia
    Gasparrini, Silvia
    Santoni, Matteo
    Cheng, Liang
    Lopez-Beltran, Antonio
    Battelli, Nicola
    Massari, Francesco
    Giunchi, Francesca
    Fiorentino, Michelangelo
    Scarpelli, Marina
    Montironi, Rodolfo
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2018, 18 (07) : 645 - 655
  • [35] Acoustic energy: A new transfection method for cancer of the prostate, cancer of the bladder and benign kidney cells
    Michel, MS
    Erben, P
    Trojan, L
    Schaaf, A
    Kiknavelidze, K
    Knoll, T
    Alken, P
    ANTICANCER RESEARCH, 2004, 24 (04) : 2303 - 2308
  • [36] Controversies in management of high-risk prostate and bladder cancer
    Loeb, Stacy
    Ribal, Maria J.
    BJU INTERNATIONAL, 2015, 116 (05) : 675 - 675
  • [37] Use of Angiotensin Converting Enzyme Inhibitors and Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer
    Kerns, S. L.
    Morlang, A.
    Lee, S. M.
    Hall, W. A.
    Peterson, D.
    Marples, B.
    Zhang, H.
    Bylund, K. C.
    Rosenzweig, D.
    de Ruyck, K.
    Rosenstein, B. S.
    Gomez CaamaNo, A.
    Vega, A.
    Parker, C.
    West, C. M. L.
    Janelsins, M.
    Chen, Y.
    Messing, E.
    Morrow, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E280 - E281
  • [38] Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer
    Reulen, Raoul C.
    de Vogel, Stefan
    Zhong, Weide
    Zhong, Zhaohui
    Xie, Li-Ping
    Hu, Zhiquan
    Deng, Yilan
    Yang, Kai
    Liang, Yuxiang
    Zeng, Xing
    Wong, Yong Chuan
    Tam, Po-Chor
    Hemelt, Marjolein
    Zeegers, Maurice P.
    PLOS ONE, 2017, 12 (06):
  • [39] Bladder cancer incidence and risk factors in men with prostate cancer: Results from cancer of the prostate strategic urologic research endeavor
    Boorjian, Stephen
    Cowan, Janet E.
    Konety, Badrinath R.
    DuChane, Janeen
    Tewari, Ashutosh
    Carroll, Peter R.
    Kane, Christopher J.
    JOURNAL OF UROLOGY, 2007, 177 (03): : 883 - 887
  • [40] Management of bladder cancer associated with prostate cancer
    Bonnal, JL
    Irani, J
    Maidenberg, M
    Theodore, C
    Mauroy, B
    PROGRES EN UROLOGIE, 2003, 13 (06): : 1286 - 1289